ISSN: 1859 - 2872
Autologous bone marrow stem cell transplantation in treatment of decompensated cirrhosis due to hepatitis B virus
Main Article Content
Keywords
Abstract
Objective: To evaluate the effectiveness of autologous bone marrow stem cell transplantation to treat hepatitis B decompensated cirrhosis. Subject and method: 60 patients with decompensated cirrhosis due to hepatitis B virus (ages 41 - 74) were enrolled in the study from June 2016 to August 2019 (of which 29 were treated for bone marrow stem cell transplantation- ABMi group; both groups were treated by general regimen for patients with cirrhosis). 250ml aspirated bone marrow fluid was used to collect BM-HSC, then was injected into the liver through hepatic artery. Patients were followed for 12 months after transplantation and their efficacy was assessed based on subclinical tests and Child-Pugh, MELD scores at 3, 6 and 12 months. Result: After treatment, albumin level improved better in the ABMi group with statistical significance with p<0.05 compared to the control group at 6 and 12 months; there was no statistically significant improvement in total bilirubin between the 2 groups, p>0.05. Child-Pugh score in ABMi group at 6 months decreased compared with before treatment with statistical significance, p<0.05, MELD score decreased at 6 months compared to before treatment, p>0.05. Complications such as: Bleeding due to varices, hepatic encephalopathy, ascites, spontaneous bacterial infections in 2 groups were similar, p>0.05. Conclusion: There was an improvement in liver function in ABMi group compared to the control group after treatment.
Keywords: Decompensated cirrhosis, hepatitis B virus.
Article Details
References
1. Lại Thanh Thùy (2016) Nghiên cứu nồng độ B-type natriuretic peptide (BNP) huyết tương ở bệnh nhân xơ gan Child-Pugh B, C. Luận văn Thạc sỹ y học, Học viện Quân y.
2. Nguyễn Thị Mai Hương (2011) Nghiên cứu chỉ số MELD trong tiên lượng bệnh nhân xơ gan. Trường Đại học Y Hà Nội.
3. Terai S et al (2006) Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 24(10): 2292-2298.
4. Kim JK et al (2010) Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. Cell Transplant 19(10): 1237-1246.
5. Child CG and Turcotte JG (1964) Surgery and portal hypertension. Major Probl Clin Surg 1: 1-85.
6. D'Amico G, Garcia-Tsao G, and Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 44(1): 217-231.
7. Huo TI et al (2005) Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: Risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 42(6): 826-832.
8. Merion RM et al (2005) The survival benefit of liver transplantation. Am J Transplant 5(2): 307-313.
9. Bambha K et al (2004) Predicting survival among patients listed for liver transplantation: An assessment of serial MELD measurements. Am J Transplant 4(11): 1798-1804.
10. Choi PC et al (2009) Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis. Liver Int 29(2): 221-226.
Article Sidebar
